Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.

Clin Cancer Res · 2022 · PMC9623232 · PMID 36044526

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

a favorable trendP = 0.21not close (p > 0.1)

For patients with an NRAS mutation (five were evaluable), a favorable trend of PFS was observed; the median PFS was 9.6 months for NRAS -mutant patients versus 6.9 months for NRAS- wild-type patients (HR, 0.41; P = 0.21).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.